Even granting that this is a challenging time for the orthopedics industry (and healthcare device providers in general), Smith & Nephew (NYSE:SNN) is struggling a little more than most. The company has been losing share in orthopedic implants like hips and knees and disappointing investors with regards to cash flow production, and the stock has been chopping around in a $20 range for about three years now. While the news on November 28 of the company's Healthpoint Biotherapeutics acquisition does bring in advanced wound care products with very good growth, Smith & Nephew is having to pay a pretty hefty price for this growth injection and this just isn't a sustainable long-term plan.

Guide To Oil And Gas Plays: We've got your comprehensive guide to oil and gas shales in North America.

Buying a Good Product That Most People Haven't Heard of
Wound care is not an especially well-appreciated segment of the healthcare market, so it's altogether understandable if most investors aren't familiar with "bioactive wound healing" or Healthpoint Biotherapeutics. Nevertheless, Smith & Nephew will be paying $782 million in cash to acquire Healthpoint and its portfolio of products build around bioactive debridement, dermal repair and wound regeneration.

The principle asset of Healthpoint is Collagenase Santyl pointment, an enzymatic debrider for dermal ulcers and burns. This product alone makes up about three-quarters of Healthpoint's sales and has been growing quite well for the company. Other products of note include Oasis for leg ulcers and Regranex for diabetic foot ulcers. Healthpoint also had a product in Phase 3 studies (HP802-247) for venous leg ulcers.

Smith & Nephew indicated that Healthpoint was on target for $190 million in sales this year, up about 25% from last year. While the company provided less information on recent margins, it seems as though Healthpoint is not strongly profitable at this point - though due at least in part to a lack of scale.

SEE: Analyzing An Acquisition Announcement

It's Logical to Get Bigger Here
With about 90% of Healthpoint's sales in the United States, this will double the company's U.S. wound care business, and grow the overall wound care business by about 20%. That will elevate wound care to about 30% of the total, so orthopedics will still be a significant part of the story post-deal.

Expanding the wound care business makes plenty of sense for Smith & Nephew. For starters, while Kinetic Concepts and Smith & Nephew have both faced challenging reimbursement decisions in wound care, it's not a market with a significant elective procedure component. What's more, it's also a market still in need of (and willing to pay for) better technology and better outcomes - persistent wounds/ulcers are a major problem for patients with limited mobility, and particularly those with diabetes.

This also happens to be a market where Smith & Nephew has scale and influence. This deal will significantly close the gap with Kinetic Concepts in terms of overall market share, and should give the company a meaningful boost in bioactive wound healing - one of the strongest growth segments in the market. Together, these two companies will have close to 50% share, with 3M (NYSE:MMM) and Convatec a ways back. What's more, this is not an easy buy ((Johnson & Johnson (NYSE:JNJ) largely exited professional wound care in 2008)), but it is one that I believe is still worthwhile and can reward a disciplined player with scale.

It's also worth noting that Smith & Nephew isn't getting anywhere fast in orthopedics. While companies like Johnson & Johnson, Zimmer (NYSE:ZMH) and Stryker (NYSE:SYK) generally saw about a 2% growth in their reconstruction businesses (hips and knees) in the third quarter, Smith & Nephew saw a 2% decline, with particular weakness in hips. Now some of this can be tied to Smith & Nephew's greater exposure to Europe (where reimbursement pressures are more intense), but it can also be tied to the fact that Smith & Nephew's products are longer in the tooth and the company has not been as innovative as its rivals.

SEE: 5 Must-Have Metrics For Value Investors

The Bottom Line
Although I like the Healthpoint deal, paying more than four times sales makes for an expensive deal these days ((though not out of line given what Shire (Nasdaq:SHPG) paid for Advanced BioHealing in 2011)). Healthpoint is a good enough asset to be worth this price, but the point stands that Smith & Nephew needs to step up its R&D/innovation game, as it cannot afford to keep buying growth at this sort of multiple.

Though I think the deal is a good one for Smith & Nephew, it doesn't change my feeling that this is a stock better left out of investors' portfolios. There are too many quality names out there ((like Medtronic (NYSE:MDT) and Covidien (NYSE:COV)) to go with Smith & Nephew instead, and if investors want to take some risk and invest in companies that need to improve their execution, St. Jude (NYSE:STJ) and Stryker look like better candidates for that sort of move.

At the time of writing, Stephen D. Simpson has owned shares of 3M since 2007.

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: ProShares UltraPro Nasdaq Biotech

    Obtain information about an ETF offerings that provides leveraged exposure to the biotechnology industry, the ProShares UltraPro Nasdaq Biotech Fund.
  3. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  9. Stock Analysis

    5 Reasons Thoratec Corp. Keeps Impressing Investors

    Learn about Thoratec Corporation and its position in its industry. Understand five key factors why the company has impressed investors.
  10. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Medical Identity Theft

    Stealing another person’s health insurance information so that ...
  3. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  4. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  5. Case Management

    Planning, processing and monitoring the healthcare services given ...
  6. Medical Patent

    A legal protection against market competition that a government ...
RELATED FAQS
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. What role does the agency problem play in the modern Health Care industry?

    Agency problems vary from health care system to health care system, and not all economists agree on the degree and desirability ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!